glp-1 gip therapy effectiveness muscle preservation loss and GLP-1R agonists use | Acta Diabetologica GLP-1 Therapy Part 1: Setting

No.:GL-VL-0109 CAS CAS:N/A Formula:Lyophilized MW:Variable (polymeric) Batch No.:QC2026-VL0109-4892 Mfg Date:2026-02-03 Test Date:2026-02-05 Sample Wt.:35.2 mg Appearance:White lyophilized powder in sealed vials Storage:2-8C, protect from light Spec.: Q/SH-VL-2026 Analytical Method & Instrumentation Method:Reversed-Phase HPLC (USP , ChP 0512) Instrument:Agilent 1260 Infinity II HPLC System (SN: DE58600) Column:Agilent ZORBAX Eclipse Plus C18, 2504.6mm, 5m (Lot: B46451) A Mobile Phase A:0.1% Trifluoroacetic acid (TFA) in Milli-Q Water (18.2 Mcm) B Mobile Phase B:0.1% TFA in Acetonitrile (HPLC Grade, Fisher Scientific) Gradient:0min5%B, 5min20%B, 20min60%B, 28min95%B, 30min95%B / Flow/Temp:1.0 mL/min / 30.0 0.5C (thermostatted) Detection:UV-DAD at 220nm (bandwidth 4nm, ref 360nm) Injection:20 L, sample conc

doi:10.4045/tidsskr.21.0142

Storage: 20C

This compound is provided as a lyophilized powder for reconstitution

For optimal results, patients should maintain consistent treatment schedules under medical supervision